Trial Profile
A phase I study of REMUNE to demonstrates the vaccine is safe for children and produced immune responses.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Feb 2017
Price :
$35
*
At a glance
- Drugs GP120-depleted HIV-1 vaccine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 23 Feb 2017 New trial record